2seventy bio Inc (TSVT)
4.785
-0.22
(-4.30%)
USD |
NASDAQ |
May 17, 16:00
4.785
0.00 (0.00%)
After-Hours: 20:00
2seventy bio Cash from Financing (TTM): 0.692M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.692M |
| December 31, 2023 | 127.39M |
| September 30, 2023 | 127.37M |
| June 30, 2023 | 127.62M |
| March 31, 2023 | 123.21M |
| Date | Value |
|---|---|
| December 31, 2022 | 166.23M |
| September 30, 2022 | 352.69M |
| June 30, 2022 | 404.49M |
| March 31, 2022 | 453.89M |
| December 31, 2021 | 354.89M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.692M
Minimum
Mar 2024
453.89M
Maximum
Mar 2022
223.85M
Average
146.92M
Median
Cash from Financing (TTM) Benchmarks
| Bristol-Myers Squibb Co | 8.278B |
| Johnson & Johnson | -21.42B |
| Macrogenics Inc | 50.49M |
| Akebia Therapeutics Inc | 9.235M |
| Tango Therapeutics Inc | 125.32M |